EP2034971-A2  See also references of WO 2007150018A2US8802128-B2  Robert R. Ruffolo, Jr. and James E. Waddell, "Receptor Interactions of Imidazolines. IX. Cirazoline is an Alpha-1 Adrenergic Agonist and an Alpha-2 Adrenergic Antagonist", The Journal of Pharmacology and Experimental Therapeutics, 1982, 222(1), 29-63.;  Tom R. Walters, "Development and Use of Brimonidine in Treating Acute and Chronic Elevations of Intraocular Pressure: A Review of Safety, Efficacy, Dose Response, and Dosing Studies", Survey of Ophthalmology, Nov. 1996, vol. 41, Supplement 1, S19-S26.;  U.S. Appl. No. 07/357,394, filed May 1989.;  U.S. Appl. No. 10/820,563, filed Apr. 2004.;  Aguilar, H.E., et al. "Vancomycin Levels After Intravitreal Injection," Retina, 1995; 15:428-432.;  Ahmad, M., et al. "Ortho Ester Hydrolysis: Direct Evidence for a Three-Stage Reaction Mechanism," Journal of American Chemistry, 1979; 101(10):2669-2677.;  Akduman, L., et al. "The early treatment diabetic retinopathy study," Clinical trials in ophthalmology: a summary and practice guide, Kertes, P.S., Conway, M.D., eds. Baltimore: Williams & Wilkins, 1998; 15-35.;  Algvere, P.V., et al. "Transplantation of RPE in Age-Related Macular Degeneration: Observations in Disciform Lesions and Dry RPE Atrophy," Graefe's Archives of Clinical Experimental Ophthalmology, 1997; 235(3):149-158.;  Anderson, L.C., et al. "An Injectable Substained Release Fertility Control System," Contraception, 1976; 13:375-384.;  Antcliff, R., et al. "The pathogenesis of edema in diabetic maculopathy," Seminars in Ophthalmology, 1999; 14:223-232.;  Apel, A., et al. "A Subconjunctival Degradable Implant for Cyclosporine Delivery in Corneal Transplant Therapy," Current Eye Research, 1995; 14(8):659-667.;  Araie, M. and Maurice, D.M. "The Loss of Fluorescein, Fluorescein Glucuronide and Fluorescein Isothiocyanate Dextran From the Vitreous by the anterior and Retinal Pathways," Experimental Eye Research, 1991; 52:27-39.;  Baker, R. "Monolithic Devices," Controlled Release of Biologically Active Agents, New York: John Wiley & Sons, 1987; 50-75.;  Barnas, U., et al. "Parameters Associated with Chronic Renal Transplant Failure," Nephrology Dialysis Transplantation, 1997; 12(Suppl 2):82-85.;  Barza, M., et al. "Pharmacokinetics of Intravitreal Carbenicillin, Cefazolin, and Gentamicin in Rhesus Monkeys," Investigative Ophthalmology & Visual Science, 1983; 24:1602-1606.;  Beck, R.W., et al. "The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple Sclerosis," New England Journal of Medicine, 1993; 329(24): 1764-1769.;  Bennett, W.M. and Barry, J.M. "Failure of Dexamethasone to Provide Adequate Chronic Immunosuppression for Renal Transplantation," Transplantation, 1979; 27(3):218-219.;  Ben-Nun, J., et al. "Pharmacokinetics of Intravitreal Injection," Investigative Ophthalmology & Visual Science 1989; 30(6):1055-1061.;  Bigar, F. and C.P. Herbort. "Corneal Transplantation," Current Opinion in Ophthalmology, 1992; 3(4):473-481.;  Bingaman, D.P., et al. "Inhibition of preretinal neovascularization in pigs by intravitreal triamcinolone acetonide," Investigative Ophthalmology and Visual Science, 1995; 36(4):S401, abstract 1867.;  Bloch-Michel, E. "Opening Address: Intermediate Uveitis," Developments in Ophthalmology: Intermediate Uveitis, W.R.F. Boeke, et al. eds. Basel: Karger, 1992; 23:1-2.;  Bodor, N., et al. "A Comparison of Intraocular Pressure Elevating Activity of Loteprednol Etabonate and Dexamethasone in Rabbits," Current Eye Research, 1992; 11(6):525-530.;  Boeke, W.R.F. "Clinical Picture of Intermediate Uveitis," Developments in Ophthalmology: Intermediate Uveitis, W.R.F. Boeke, et al. eds. Basel: Karger 1992; (23):20-27.;  Bolen, J.B. "Nonreceptor tyrosine protein kinases," Oncogene, 1993; 8(8):2025-2031.;  Budavari, S., et al. eds. The Merck Index, 12th ed. Rahway, NJ: Merck and Co., 1996; Table of Contents only.;  Bundgaard, H. and Moss, J. "Prodrugs of Peptides IV: Bioreversible Derivatization of the Pyroglutamyl Group by N-Acylation and N-Aminomethylation to Effect Protection against Pyroglutamyl Aminopeptidease," Journal of Pharmaceutical Sciences, 1989; 78(2):122-126.;  Burdon, M.A. and P. McDonnell. "A Survey of Corneal Graft Practice in the United Kingdom," Eye, 1995; 9(Suppl):6-12.;  Chacko, D.M., et al. "Survival and Differentiation of Cultured Retinal Progenitors Transplanted in the Subretinal Space of the Rat," Biochemical and Biophysical Research Communications, 2000; 268(3):842-846.;  Challa, J.K., et al. "Exudative Macular Degeneration and Intravitreal Triamcinolone: 18 month follow up," Australian and New Zealand Journal of Ophthalmology, 1998; 26:277-281.;  Chang, David, et al. "Phase II results of an intraocular steroid delivery system for cataract surgery," Ophthalmology, Jun. 1996; 106(6):1172-1177.;  Chang, M., et al. "Basic Science and Clinical Aspects of Wound Healing in Glaucoma Filtering Surgery," Journal of Ocular Pharmacology and Therapeutics, 1998; 14(1):75-95.;  Charles, J., et al. "Use of Bioerodible Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery in Rabbits," Ophthalmology, Apr. 1991; 98(4):503-508.;  Cheng, Cheng-Kuo, et al. "Intravitreal Sustained-Release Dexamethasone Device in the Treatment of Experimental Uveitis," Investigative Ophthalmology & Visual Science, Feb. 1995; 36(2):442-453.;  Clarkson, J.G. "Central retinal vein occlusion," Retina, 3rd ed. Ryan, S., Schachat, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1368-1375.;  Cuff, G. and Raouf, F. "A Preliminary Evaluation of Injection Molding as a Technology to Produce Tablets," Pharmaceutical Technology, 1998; 96-106.;  Davis, P.A., et al. "Intraocular Implant for Controlled 5-Fluorouracil Release," Proceedings of the 19th International Symposium of Controlled Release Bioactive Materials, 1992; 19:339-340.;  De Jong, S.J., et al. "New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus," Polymer, 2001; 42:2795-2802.;  Di Colo, G. "Controlled Drug Release From Implantable Matrices Based On Hydrophobic Polymers," Biomaterials, 1992; 13(12):850-856.;  Dick, J., et al. "Macular edema," Retina, 3rd ed. Ryan, S., Schachat, A.P., eds. St. Louis, MO: CV Mosby; 2001; 967-979.;  Dinning, W.J. "Intermediate Uveitis: history, terminology definition pars planitis: systemic disease associations," Developments in Ophthalmology: Intermediate Uveitis, W.R.F. Boeke, et al. eds. Basel: Karger, 1992; 3-8.;  Dohlman, C., et al. "Treatment of corneal edema with a buried implant," Transactions: American Academy of Ophthalmology and Otolaryngology, Mar.-Apr. 1966; 267-280.;  Enyedi, Laura, et al. "An Intravitreal Device Providing Sustained Release of Cyclosporine and Dexamethasone," Current Eye Research, 1996; 15(5):549-557.;  Enzmann, V., et al. "Immunological Problems of Transplantation into the Subretinal Space," Acta Anatomica, 1998; 162(2-3):178-183.;  Fatt, I. "Flow and Diffusion In the Vitreous Body of The Eye," Bulletin of Mathematical Biology, 1975; 37:85-90.;  Fekrat, S. and Finkelstein, D. "The Central Vein Occlusion Study," Clinical trials in ophthalmology: a summary and practice guide, Kertes, P.S., Conway, M.D., eds. Baltimore, MD: Williams & Wilkins, 1998; 129-143.;  Frank, R.N. "Etiologic mechanisms in diabetic retinopathy," Retina, 3rd ed. Ryan, S., Schachat,, A.P., eds. St. Louis, MO: CV Mosby; 2001; 1259-1294.;  Friedrich, S., et al. "Finite Element Modeling of Drug Distribution in the Vitreous Humor of the Rabbit Eye," Annals of Biomedical Engineering, 1997; 25:303-314.;  Gennaro, A.R. ed. Remington: The Science and Practice of Pharmacy, 19th Ed. Easton, PA: Mack Publishing Company, 1995; Table of Contents only, xv-xvi.;  Gillies, M.C., et al. "Safety of an intravitreal injection of triamcinolone," Archives of Ophthalmology, Mar. 2004; 122:336-340.;  Gilman, A.G., et al. eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th Ed. New York: Pergamon Press, 1990; Table of Contents only, xi-xvi.;  Gould, L., et al. "Fifty:fifty Poly (DL Glycolic Acid-Lactic Acid) Copolymer as a Drug Delivery System for 5-Fluorouracil: A Histopathological Evaluation," Canadian Journal of Ophthalmology, 1994; 29(4):168-171.;  Greenfield, R.S., et al. "Evaluation in Vitro of Adriamycin Immunoconjugates Synthesized Using an Acid-sensitive Hydrazone Linker," Cancer Research, 1990; 50:6600-6607.;  Guan, D., et al. "The Therapeutic Window of Cyclosporine in Chinese Recipients of Renal Transplantation," Transplantation Proceedings, 1995; 27(1):850-851.;  Hainsworth, Dean P., et al. "Sustained Release Intravitreal Dexamethasone," Journal of Ocular Pharmacology and Therapeutics, 1996; 12(1):57-63.;  Hari, P. and Srivastava, R.N. "Pulse Corticosteroid Therapy with Methylprednisolone or Dexamethasone," Indian Journal of Pediatrics, 1998; 65(3):557-560.;  Haynes, Robert C. Jr. "Adrenocorticotropic Hormone; Adrenocortical Steroids and their Synthetic Analogs; Inhibitors of the Synthesis and Actions of Adrenocortical Hormones," Goodman and Gilman's: The pharmacological Basis of Therapeutics, 8th Ed. New York: Pergamon Press, 1990; 1431-1462.;  Hayreh, S.S. "Posterior Drainage of the Intraocular Fluid From the Vitreous," Experimental Eye Research, 1996; 5:123-144.;  Heller, J. "Bioerodible Hydrogels," Hydrogels in Medicine and Pharmacy, vol. 3: Properties and Applications, Peppas, N. A. ed. Boca Raton: CRC Press, 1987; 138-149.;  Hirano, T. "Clinical Significance of Glucocorticoid Pharmacodynamics Assessed by Antilymphocyte Action in Kidney Transplantation," Transplantation, 1994; 57(9):1341-1348.;  Hoeckel, M., et al. "Prevention of Peritoneal Adhesions in the Rat With Sustained Intraperitoneal Dexamethasone Delivered by a Novel Therapeutic System," Annales Chirurgiae et Gynaecologiae, 1987; 76(6):306-313.;  Jackanicz, T., et al. "Polyactic Acid As a Biogradable Carrier for Contraceptive Steroids" Contraception, 1973; 8(3):227-234.;  Jaffe, G.J., et al. "Safety, Efficacy, and Pharmacokinetics of an Intravitreal Fluocinolone Sustained Drug Delivered System," Investigative Ophthalmology & Visual Science, 1999; 40(4):S988, abstract 5195.;  Jampel, H., et al. "Glaucoma Filtration Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks," Archives of Ophthalmology, Mar. 1990; 108(3):430-435.;  Jay, W.M., et al. "Intravitreal Ceftazidime in a Rabbit Model: Dose-and Time-Dependent Toxicity and Pharmacokinetic Analysis," Journal of Ocular Pharmacology, 1987; 3(3):257-262.;  Jellinek, D., et al. "Inhibition of Receptor binding by High-affinity RNA Ligands to Vascular Endothelial Growth Factor," Biochemistry, 1994; 33:10450-56.;  Jennings, T., et al. "Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema," Japanese Journal of Ophthalmology, 1988; 32(4):385-391.;  Johnson, F. and Maurice, D. "A Simple Method of Measuring Aqueous Humor Flow With Intravitreal Fluoresceinated Dextrans," Experimental Eye Research, 1984; 39:791-805.;  Jonas, J.B., et al. "Intraocular pressure after intravitreal injection of triamcinolone acetonide," British Journal of Ophthalmology, 2003; 87:24-27.;  Kane, A., et al. "Intravitreal Injection of Gentamicin in Rabbits," Investigative Ophthalmology & Visual Science, 1981; 20(5):593-597.;  Kendall, R.L and K.A. Thomas. "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," Proceedings of the National Academy of Science USA, 1994; 90:10705-09.;  Kher, V., et al. "Low-Dose Dexamethasone_An Alternative Therapy for Acute Renal Allograft Rejection," Transplantation Proceedings, 1992; 24(5):1725.;  Kim, K.J., et al. "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo," Nature, 1993; 362(6423):841-844.;  Kimura, H. and Ogura, Y. "Biodegradable Polymers for Ocular Drug Delivery," Ophthalmologica, 2001; 215:143-155.;  Kinsella, J.L., et al. "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," Experimental Cell Research, 1992; 199:56-62.;  Kochinke, F. and Wong, V.G. "Biogradable Drug Delivery System for Uveitis Treatment, Oculex Pharmaceuticals, Inc.," Slide Presentation, 1996; total pp. 20.;  Kochinke, F., et al. "Biodegradable Drug Delivery System for Uveitis Treatment," Investigative Ophthalmology & Visual Science, Feb. 1996; 37(3):S42.;  Kralinger, M.T., et al. "Slow Release of Acetysalicyclic Acid by Intravitreal Silicone Oil," Retina: The Journal of Retinal and Vitreous Diseases, 2001; 21(5):513-520.;  Kunou, Noriyuki, et al. "Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate," Journal of Biomedical Materials Research, 2000; 51(4):635-641.;  Kwak, H.W. and D'Amico, D.J. "Evaluation of the Retinal Toxicity and Pharmacokinetics of Dexamethasone After Intravitreal Injection," Archives of Ophthalmology, 1992; 110:259-266.;  Laurent, U.B.G. and Fraser, J.R.E. "Turnover of Hyaluronate in the Aqueous Humor And Vitreous Body of the Rabbit," Experimental Eye Research, 1983; 36:493-504.;  Lee, D., et al. "Complications of Subconjunctival 5-Fluorouracil Following Glaucoma Filtering Surgery," Ophthalmic Surgery, Mar. 1987; 18(3):187-190.;  Lee, D., et al. "Glaucoma Filtration Surgery in Rabbits Using Bioerodible Polymers and 5-Fluorouracil," Ophthalmology, Dec. 1987; 94(12):1523-1530.;  Lee, D., et al. "The Use of Bioerodible Polymers and 5-Fluorouracil in Glaucoma Filtration Surgery," Investigative Ophthalmology & Visual Science, Nov. 1988; 29(11):1692-1697.;  Lee, K.Y. and Wong, V.G. "Dexamethasone Posterior Segment Drug Delivery System for Treatment of Severe Uveitis," American Uveitis Society, 1999; Abstract.;  Lee, V.H.L., et al. "Drug Delivery to the Posterior Segment" Retina, 3rd ed. T.E. Ogden and A.P. Schachat eds. St. Louis: CV Mosby, 1989; 483-498.;  Leopold, I.H. "Nonsteroidal and steroidal anti-inflammatory agents," Surgical pharmacology of the Eye, Sears, M., Tarkkanen, A., eds. New York: Raven Press, 1985; 83-133.;  Marcon, I. "A double-masked comparison of betaxolol and levobunolol for the treatment of primary open-angle glaucoma," Arquivos Brasileiros de Oftalmologia, 1990; 53(1):27-32.;  Mariani, M., et al. "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," Proceedings of the American Association for Cancer Research, 1994; 35:381, abstract 2268.;  Maurice, D.M. "The Exchange of Sodium Between The Vitreous Body and The Blood And Aqueous Humour," Journal of Physiology, 1957; 137:110-125.;  Maurice, D.M. "Flow of Water Between Aqueous and Vitreous Compartments in the Rabbit Eye," American Journal of Physiology, 1987; 252 (1):F104-F108.;  Maurice, D.M. "Micropharmaceutics of the Eye," Ocular Inflammation and Therapeutics, 1983; 1:97-102.;  Maurice, D.M. and Mishima, S. "Ocular Pharmacokinetics," Pharmacology of the Eye, M.L. Sears ed. New York: Springer-Verlag, 1984; 19-116.;  Meadows, D.L., et al. "Ocular Drug Delivery with Subconjunctival Implants," Proceedings of the International Symposium on Controlled Release of Bioactive Materials, Controlled Release Society, Inc., 1994; 21:593-594.;  Miller, R., et al. "Degradation Rates of Oral Resorbable Implants (Polylactates and Polyglycolates): Rate Modification with Changes in PLA/PGA Copolymer Ratios," Journal of Biomedical Materials Research, 1977; 11(5):711-719.;  Mittal, R., et al. "Treatment of Acute Rejection in Live Related Renal Allograft Recipients: A Comparison of Three Different Protocols," Nephron, 1977; 77(2):186-189.;  Molfino, F., et al. "IOP-lowering effect of dorzolamide 2% versus brimonidine tartrate 0.2%. A prospective randomized cross over study," Investigative Ophthalmology & Visual Science, Mar. 1998; 39(4):S481.;  Morita Y., et al. "Intravitreous delivery of dexamethasone sodium m-sulfobenzoate from poly (DL-lactic acid) implants," Biological & Pharmaceutical Bulletin, Feb. 1998; 21(2):188-90.;  Morita, Y., et al. "Polymer Blend Implant for Ocular Delivery of Fluorometholone," Biological & Pharmaceutical Bulletin, 1998; 21(1):72-75.;  Moseley, H., et al. "Routes of Clearance of Radioactive Water From The Rabbit Vitreous," British Journal of Ophthalmology, 1984; 68:145-151.;  Nakamura, O., et al. "Inhibition of neovascularization and tumor growth by dexamethasone," No To Shinkei (Brain and Nerve), Jan. 1992; 44(1):37-41.;  Nauck, M., et al. "Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells," European Journal of Pharmacology, 1998; 341:309-315.;  Nauck, M., et al. "Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids," American Journal of Respiratory Cell and Molecular Biology, 1997; 16:398-406.;  Ogden, T.E., et al. eds. Retina_Basic Science and Inherited Retinal Disease vol. 1, St. Louis: CV Mosby, 1994; Table of Contents, xxiii-xxix.;  Ohtori, A. and Tojo, K. "In vivo/in Vitro Correlation of Intravitreal Delivery of Drugs With the Help of Computer Simulation," Biological & Pharmaceutical Bulletin, 1994; 17(2):283-290.;  Olsen, T.W., et al. "Human Scleral Permeability: Effects of Age, Cryotherapy, Transscleral Diode Laser, and Surgical Thinning," Investigative Ophthalmology & Visual Science, 1995; 36(9):1893-1903.;  Oplinger, N. L., et al. "A Comparison of Corneal Autografts With Homografts," Ophthalmic Surgery and Lasers, 1998; 29(4):305-308.;  Orth, D. "The branch vein occlusion study," Clinical trials in ophthalmology: A summary and practice guide, Kertes, P, and Conway, M, eds., Baltimore, MD: Williams & Wilkins, 1998: 113-127.;  Park, T.G., et al. "A new preparation method for protein loaded poly (D,L-lactic-co-glycolic acid) microspheres and protein release mechanism study," Journal of Controlled Release, 1998; 55: 181-191.;  Patel, N. P., et al. "Indications for and Outcomes of Repeat Penetrating Keratoplasty, 1989-1995," Ophthalmology, 2000; 107(4):719-724.;  Pearson, P.A., et al. "Clearance and Distribution of Ciprofloxacin After Intravitreal Injection," Retina, 1993; 13:326-330.;  Pe'er, J., et al. "Vascular endothelial growth factor by platelet-activating factor upregulation in human central retinal vein occlusion," Ophthalmology, 1998; 105:412-416.;  Peyman, G.A. and Herbst, R. "Bacterial endophthalmitis," Archives of Ophthalmology, 1974; 91(5):416-418.;  Peyman, G.A., et al. "A Technique for Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration Secondary to Extensive Subfoveal Scarring," Ophthalmic Surgery, 1991; 22(2):102-108.;  Pinar, V. "Intermediate Uveitis," Massachusetts Eye & Ear Infirmary Immunology Service, Boston.;  Plowman, G.D., et al. "Receptor Tyrosine Kinases as Targets for Drug Intervention," Drug News & Perspectives, 1994; 7(6): 334-339.;  Rao, K.V., et al. "Successful Renal Transplantation in a Patient With Anaphylactic Reaction to Solu-Medrol (Methylprednisolone Sodium Succinate)," American Journal of Medicine, 1982; 72(1):161-163.;  Rao, N.A., et al. "Intraocular Inflammation and Uveitis," Basic and Clinical Science Course, Section 9, San Francisco: American Academy of Ophthalmology, 1998-1999; 57-80, 102-103, 152-156.;  Renfro, L. and Snow, J.S. "Ocular Effects of Topical and Systemic Steroids," Dermatologic Clinics, 1992; 10:505-512.;  Riordan-Eva, P., et al. "Orbital floor steroid injections in the treatment of uveitis," Eye, 1994; 8(1):66-69.;  Robin, Jeffrey B., et al. "The Histopathology of Corneal Neovascularization," Archives of Ophthalmology, 1985; 103(2):284-287.;  Roff, W.J. and Scott, J.R. eds. Handbook of Common Polymers, Cleveland: CRC Press, 1971; Table of Contents.;  Rootman, D.S., et al. "Toxicity and Pharmacokinetics of Intravitreally Injection Ciprofloxacin in Rabbit Eyes," Canadian Journal of Ophthalmology, 1992; 27(6):277-282.;  Sasaki, H., et al. "Drug Absorption Behavior After Periocular Injections," Biological & Pharmaceutical Bulletin, 1999; 22(9):956-960.;  Schindler, R.H., et al. "The Clearance of Intravitreal Triamcinolone Acetonide," American Journal of Ophthalmology, 1982; 93(4):415-417.;  Scholes, G.N., et al. "Clearance of Triamcinolone From Vitreous," Archives of Ophthalmology, 1985; 103(10):1567-1569.;  Schwartz, B. "The Response of Ocular Pressure to Corticosteroids," International Ophthalmology Clinics, 1966; 6:929-989.;  Shields, Bruce M. "Glaucoma Filtering Procedures," A Study Guide for Glaucoma, Baltimore: Williams & Wilkins, 1982; 453-476.;  Skalka, H.W. and Prchal, J.T. "Effect of Corticosteroids on Cataract Formation," Archives of Ophthalmology, 1980; 98(10):1773-1777.;  Smith, T., et al. "Sustained-release subconjunctival 5-Fluorouracil," Ophthalmic Surgery and Lasers, Sep. 1996; 27(9):763-767.;  Stewart, W., et al. "Washout periods for brimonidine 0.2% and latanoprost 0.005%," American Journal of Ophthalmology, Jun. 2001; 131(6):798-799.;  Taba, K.E., et al. "Intravitreal sustained release fluocinolone implant inhibits experimental choroidal neovascularization," Investigative Ophthalmology & Visual Science, Mar. 1999; 40(4):S172, abstract 920.;  Takano, S.,et al. "Inhibition of Angiogenesis by a Novel Diaminoanthraquinone that Inhibits Protein Kinase C," Molecular Biology of the Cell, 1993; 4:358A, abstract 2076.;  Tan, D.T.H., et al. "Randomized Clinical Trial of a New Dexamethasone Delivery System (Surodex) for Treating of Post-Cataract Surgery Inflammation," Ophthalmology, 1999; 106(2):223-231.;  Tennant, J.L. "Cystoid maculopathy," Current concepts in cataract surgery: selected proceedings of the fifth biennial cataract surgical congress, Emery, J.M. ed. St. Louis: CV Mosby, 1978; 360-362.;  Theng, J.T.S., et al. "Pharmacokinetic and Toxicity Study of an Intraocular Cyclosporine DDS in the Anterior Segment of Rabbit Eyes," Investigative Ophthalmology & Visual Science, Nov. 2003; 44(11):4895-4899.;  Tracy, M.A., et al. "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro," Biomaterials, 1999; 20:1057-1062.;  Tsubota, K. "Ocular Surface Management in Corneal Transplantation, A Review," Japanese Journal of Ophthalmology, 1999; 43(6):502-508.;  The United States Pharmacopeia, The National Formulary, "USP 24/NF 19," 2000; 1941-1951.;  Weisbecker, C.A., et al., eds. Physicians' Desk Reference for Ophthalmology 27th ed., Montvale, NJ: Medical Economics Company, 1998; 7-8, 278-279.;  Wingate, R.J., et al. "Intravitreal Triamcinolone and Elevated Intraocular Pressure," Australian and New Zealand Journal of Ophthalmology, Dec. 1999; 27(6):431-2.;  Wright, P.S., et al. "Inhibition of Angiogenesis In Vitro and In Ovo with an Inhibitor of Cellular Protein Kinases, MDL 27032," Journal of Cellular Physiology, 1992; 152(3):448-457.;  Xu, J., et al. "Permeability and Diffusion in Vitreous Humor: Implications for Drug Delivery," Pharmaceutical Research, 2000; 17(6):664-669.;  Zhou, T., et al. "Development of a Multiple-Drug Delivery Implant for Introcular Management of Proliferative Vitreoretinopathy," Journal of Controlled Release, 1998; 55:281-295.;  U.S. Appl. No. 60/587,092, filed Jul. 12, 2004, Whitcup.;  U.S. Appl. No. 07/386,835, filed Jul. 27, 1989, Chan et al.;  U.S. Appl. No. 11/303,462, filed Dec. 15, 2005, Hughe et al.;  U.S. Appl. No. 11/473,947, filed Jun. 23, 2006, Whitcup et al.;  Ahmad, M. et al., J. Amer. Chem. Soc. 101, 2669 (1979).;  Andreau, K., et al., Induction of apoptosis by dexamethasone in the B cell lineage, Immunopharmacology Jul. 1998:40(1):67-76.;  Beck, R.W., et al., A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group, N. Engl J Med. Feb. 27, 1992;326(9):634-5.;  Bito, L. Z., Applied Pharmacology in the Medical Treatment of Glaucomas, Drance, S. M. and Neufeld, A. H. eds., New York, Grune & Stratton, 1984, pp. 477-505.;  Bito, L. Z., Arch. Ophthalmol. 105, 1036 (1987).;  Bito, L. Z., Biological Protection With Prostaglandins Cohen, M. M., ed., Boca Raton, Fla., CRC Press Inc., 1985, pp. 231-252.;  Brubaker, Mechanism of Action of Bimatoprost (Lumigan(TM)), Surv Ophthalmol 45 (Suppl 4):S347-S351 (2001).;  Chen, et al., Lumigan(R): A Novel Drug for Glaucoma Therapy, Optom In Pract, 3:95-102 (2002).;  Coleman, et al., A 3-Month Randomized Controlled Trial of Bimatoprost (LUMIGAN) versus Combined Timolol and Dorzolamide (Cosopt) in Patients with Glaucoma or Ocular Hypertension, Ophthalmology 110(12): 2362-8 (2003).;  Druilhe, A., et al., Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action, Apoptosis Oct. 2003;8(5):481-95.;  Encyclopedia of Polymer Science and Technology, vol. 3, published by Interscience Publishers, Inc., New York, latest edition.;  Goldberg, Ivan, in Aust. Preser. 25, 142 (2002).;  Goodman & Gilman's The Pharmacological Basis of Therapeutics, ninth edition, McGraw Hill (1996).;  Heller, Biodegradable Polymers in Controlled Drug Delivery, In: CRC Critical Reviews in Therapeutic Drug Carrier Systems, vol. 1, CRC Press, Boca Raton, FL 1987, pp. 39-90.;  Heller, J. et al., Methods in Enzymology 112, 422-436 (1985).;  Heller, J., J. Adv. Polymer Sci. 107, 41 (1993).;  Inoue, M.; et al., Vitreous Concentrations Of Triamcinolone Acetonide In Human Eyes After Intravitreal Or Subtenon Injection. Am. J. Ophthalmol. 2004;138:1046-8.;  Jaffe GJ, et al., Safety And Pharmacokinetics Of An Intraocular Fluocinolone Acetonide Sustained Delivery Device, Invest. Ophthalmol. Vis. Sci. 2000;41:3569-75.;  Jeong, J. H. et al, Bioconj. Chem. 14, 473 (2003).;  Kang SW et al., Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema, Arch Ophthalmol. May 2006;124(5):653-8.;  Mathebula, S. D. in The South African Optometrist, Sep. 2005, pp. 89-95.;  Migita, K., et al., Apoptosis Induction In Human Peripheral Blood T Lymphocytes By High-Dose Steroid Therapy. Transplantation 1997;63:583-7.;  Nilsson et al., Invest. Ophthalmol. Vis. Sci. 28(suppl), 284 (1987).;  Rahil, J. et al, J. Am. Chem. Soc. 103, 1723 (1981).;  Schimmer B.P. and Parker K.L. ACTH: Adrenocortical Steroids and their Synthetic Analogs, 10th ed. in The Pharmacological Basis of Therapeutics 1657 (Hardman J.G. and Limbard L.L., editors, McGraw-Hill, 2001).;  Scott, J. R. and W. J. Roff, Handbook of Common Polymers, Section 64, (1971) published by CRC Press, Cleveland, Ohio.;  Siebold et al., Prodrug 5, 3 (1989).;  Starr, M. S., Exp. Eye Res. 1971, 11, pp. 170-177.;  Turcotte, J.G., et al., Rejection Crises In Human Renal Transplant Recipients: Control With High Dose Methylprednisolone Therapy, Arch. Surg. 1972;105:230-6.;  USP 23; NF 18 (1995) pp. 1790-1798.;  Watson et al., Ophthalmology 103:126 (1996).;  Woodward et al., AGN 2024 (Lumigan(R)): A Synthetic Prostamide Analog that Lowers Primate Intraocular Pressure by Virtue of Its Inherent Pharmacological Activity, ARVO 2002.;  Woodward et al., The Pharmacology of Bimatoprost (LumiganTM), Surv Ophthalmol 45 (Suppl 4) S337-S345 (2001).;  U.S. Appl. No. 10/837,356, filed Apr. 30, 2004.;  U.S. Appl. No. 11/118,288, filed Apr. 29, 2005.;  U.S. Appl. No. 11/474,149, filed Jun. 23, 2006.;  U.S. Appl. No. 11/932,373, filed Oct. 31, 2007.;  U.S. Appl. No. 12/031,656, filed Feb. 14, 2008.;  U.S. Appl. No. 12/031,659, filed Feb. 14, 2008.;  U.S. Appl. No. 13/356,934, filed Jan. 24, 2012.;  U.S. Appl. No. 13/613,636, filed Sep. 13, 2012.